uniQure N.V. (QURE)
| Market Cap | 654.06M |
| Revenue (ttm) | 16.10M |
| Net Income (ttm) | -198.97M |
| Shares Out | 62.29M |
| EPS (ttm) | -3.46 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 16,840,984 |
| Open | 9.19 |
| Previous Close | 15.63 |
| Day's Range | 8.96 - 11.09 |
| 52-Week Range | 7.76 - 71.50 |
| Beta | 0.77 |
| Analysts | Buy |
| Price Target | 50.33 (+379.33%) |
| Earnings Date | Mar 2, 2026 |
About QURE
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase ... [Read more]
Financial Performance
In 2025, uniQure's revenue was $16.10 million, a decrease of -40.64% compared to the previous year's $27.12 million. Losses were -$198.97 million, -16.94% less than in 2024.
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for QURE stock is "Buy." The 12-month stock price target is $50.33, which is an increase of 379.33% from the latest price.
News
uniQure N.V. (QURE) Q4 2025 Earnings Call Transcript
uniQure N.V. (QURE) Q4 2025 Earnings Call Transcript
FDA tells UniQure study data insufficient for brain disorder therapy application
UniQure said on Monday the U.S. Food and Drug Administration has told the company that its data from an early-to-mid stage trial would not support a marketing application for its brain disorder gene t...
uniQure Announces 2025 Financial Results and Provides Recent Company Updates
~ Held Type A meeting with FDA to discuss AMT-130 for Huntington's disease; Company evaluating Phase III development considerations and plans to request follow-up Type B meeting in the second quarter ...
uniQure: Shares Tumble On Fresh FDA Controversy - What Investors Should Know
uniQure N.V. shares plunged >30% after FDA Commissioner comments were interpreted as negative for AMT-130, its Huntington's gene therapy candidate. QURE's AMT-130 showed statistically significant slow...
QURE INVESTOR REMINDER: uniQure N.V. Investors Have Until April 13, 2026 To Seek Lead Plaintiff Role
NEW YORK--(BUSINESS WIRE)--If you have suffered a loss on your uniQure N.V. (“uniQure” or the “Company”) (NASDAQ:QURE) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at investigat...
uniQure to Announce 2025 Financial Results
~ uniQure to host earnings call on Monday, March 2, 2026 at 8:00 a.m. ET ~ ~ uniQure to host earnings call on Monday, March 2, 2026 at 8:00 a.m. ET ~
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 13, 2026 in uniQure Lawsuit - QURE
NEW YORK, Feb. 19, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of uniQure N.V. (NASDAQ: QURE).
UniQure N.V. (QURE) Securities Fraud: Contact Berger Montague To Discuss Your Rights
Philadelphia, Pennsylvania--(Newsfile Corp. - February 18, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against uniQure N.V. (NASDAQ: Q...
UNIQURE N.V. (QURE) INVESTOR ALERT Investors With Large Losses in uniQure N.V.
NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquir...
Diamond Hill International Strategy Q4 2025 Portfolio Review
Diamond Hill International Strategy returned 3.87% (net of fees) and the MSCI ACWI ex USA Index returned 5.05%. Sumitomo Densetsu, a Japanese electrical contractor, benefited from a takeover bid by Da...
Early uniQure Fabry Trial Shows Lasting Enzyme Boost, Safety Watch
uniQure N.V. (NASDAQ: QURE) on Friday announced updated preliminary safety and exploratory efficacy data from 11 patients in its Phase 1/2a trial of AMT-191.
uniQure Announces Updated Preliminary AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease
~ Supraphysiological expression of α-Gal A activity maintained for over a year in longest treated patient as of data cutoff date ~
Alger Small Cap Focus Fund Q4 2025 Portfolio Update
Class A shares of the Alger Small Cap Focus Fund outperformed the Russell 2000 Growth Index during the fourth quarter of 2025. Exact Sciences Corporation, Guardant Health, Inc., and Natera, Inc. were ...
uniQure Announces Type A Meeting Scheduled with FDA
LEXINGTON, Mass. and AMSTERDAM, Jan. 09, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,...
uniQure: Now What?
uniQure faces a major setback as the FDA reversed its stance on using external controls for AMT-130's approval, delaying its BLA submission. QURE's pivotal Phase 1/2 trial showed 75% slowing in cUHDRS...
What's Going On With uniQure Stock On Tuesday?
uniQure NV (NASDAQ: QURE) stock has plunged around 31% over the last month, as per data from Benzinga Pro.
Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years
- 94% of patients (51 of 54) remained free from the burden of continuous prophylaxis treatment through five years following a single infusion of HEMGENIX, demonstrating sustained therapeutic benefit- ...
Why uniQure Stock Is Trading Lower After FDA Meeting Update
uniQure N.V. (NASDAQ: QURE) stock is trading lower on Thursday.
uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease
LEXINGTON, Mass. and AMSTERDAM, Dec. 04, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,...
Diamond Hill International Strategy Q3 2025 Performance Review
Though positive on an absolute basis, Diamond Hill International Strategy portfolio modestly trailed the benchmark during the quarter. From a sector perspective, health care and information technology...
uniQure N.V. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - QURE
LOS ANGELES , Nov. 14, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of uniQure N.V. ("uniQure" or "the Company") (NASDAQ: QURE) for violation...
QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with the Schall Law Firm
LOS ANGELES, Nov. 12, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of uniQure N.V. (“un...
From Setback To Surge: UniQure's Huntington's Hope Is Poised For Upside
UniQure stock is rated a Buy with a $66 price target, offering upside after recent FDA pushback on AMT-130 Huntington's therapy trial design. AMT-130 is the first disease-modifying therapy for Hunting...
uniQure N.V. (QURE) Q3 2025 Earnings Call Transcript
uniQure N.V. ( QURE) Q3 2025 Earnings Call November 10, 2025 8:30 AM EST Company Participants Chiara Russo - Senior Director of Investor Relations Matthew Kapusta - CEO & Executive Director Walid Abi...
uniQure Announces Third Quarter 2025 Financial Results and Provides Corporate Update
~ Announced pivotal topline data from Phase I/II study of AMT-130 in Huntington's disease met its primary and key secondary endpoints, demonstrating statistically significant slowing of disease progre...